Veralto Corporation (VLTO) has seen considerable activity within the biotech investment community over recent times. They received a "Buy" rating from Weiss Ratings and reported promising Q2 2025 results. The company has also scheduled its Q3 2025 earnings call. Share movements have been evident, with significant entities such as Atria Wealth Solutions and Loring Wolcott & Coolidge Fiduciary Advisors selling off their shares, while firms like MGO One Seven and Allspring Global Investments buying further into the company. Veralto’s stock has seen a general rise, with a noted 2% increase following their last earnings report. The company's equity positions were further bolstered by significant buys from companies like QRG Capital Management and Generali Asset Management. Their upcoming Q2 results are eagerly anticipated, with Veralto’s recent history of surpassing Q2 earnings and revenue estimates suggesting further growth could be on the horizon. Lastly, Veralto's commitment of €20M to Emerald's Water Innovation fund exemplifies their continued investment in innovative solutions.
Veralto Corporation VLTO News Analytics from Mon, 06 Jan 2025 08:00:00 GMT to Sat, 25 Oct 2025 18:38:17 GMT -
Rating 6
- Innovation 5
- Information 7
- Rumor 4
